WebDoctor Encyclopedia

Acute leukaemias Childhood

Myeloid sarcoma (chloroma)

Myeloid sarcoma, also called chloroma, is a solid lump of leukaemia cells that grows outside the bone marrow. It can appear before, with or after acute myeloid leukaemia and is treated like AML.

Medically reviewed Last reviewed November 15, 2026

What is myeloid sarcoma?

Myeloid sarcoma is a solid tumour made of immature myeloid blood cells (myeloblasts) that grows outside the bone marrow. It is a form of acute myeloid leukaemia (AML) that collects as a lump in tissues such as the skin, lymph nodes, bone or soft tissue.

It has several other names. The oldest is chloroma, from the Greek word for green, because the tumours can look greenish when cut. This colour comes from an enzyme called myeloperoxidase inside the leukaemia cells.

It is also called granulocytic sarcoma or extramedullary myeloid tumour. Despite the word “sarcoma”, it is not a true sarcoma of connective tissue. It is a leukaemia.

Myeloid sarcoma can appear before, at the same time as or after AML is found in the blood and bone marrow. It can also be the first sign that another bone marrow disorder, such as a myelodysplastic syndrome or chronic myeloid leukaemia, has turned into acute leukaemia.

Even when the tumour appears on its own, it almost always behaves like AML. It is therefore treated as AML, usually with intensive chemotherapy.

1. Key facts at a glance

Feature Details
Type of disease Extramedullary (outside the marrow) tumour form of acute myeloid leukaemia
How common Found in roughly 2-9% of people with AML; isolated cases are much rarer
Typical age Any age; adults median about 55-60; relatively more common in children with AML
Common sites Skin, lymph nodes, soft tissue, bone, eye socket, breast, testis, gut, spine
Link with AML Occurs with, before or after AML; isolated tumours usually progress to AML without treatment
Main treatment AML-type chemotherapy; radiotherapy; stem cell transplant for some
Outlook Similar to AML with the same genetic features

2. When myeloid sarcoma occurs

Situation Description
Isolated (de novo) A tumour with no leukaemia found in the blood or bone marrow; most progress to AML within months if not treated
With AML Present at the same time as AML in the marrow; the most common situation
At relapse The first sign that AML has returned, including after a stem cell transplant
Transformation A sign that MDS, a myeloproliferative neoplasm or chronic myeloid leukaemia has become acute leukaemia

Myeloid sarcoma after a stem cell transplant is well recognised. It often appears in unusual places, such as the breast, testis or skin, and may occur even when the bone marrow is still clear.

3. Causes and risk factors

Myeloid sarcoma develops for the same reasons as AML. Damage to the DNA of blood-forming cells causes them to multiply without maturing properly.

Why some leukaemias form solid lumps outside the marrow is not fully understood. Changes in adhesion molecules, which help cells stick to tissues, are thought to play a part.

Factor Notes
Certain genetic types of AML More common in AML with t(8;21) (RUNX1::RUNX1T1), inv(16) (CBFB::MYH11), KMT2A rearrangements and NPM1 mutations
Monocytic AML AML with monocytic features more often spreads to skin, gums and other tissues
Young age Children with AML develop myeloid sarcoma relatively more often, especially around the eye with t(8;21)
Previous bone marrow disorders MDS, myeloproliferative neoplasms and chronic myeloid leukaemia can transform
Previous transplant Relapse after transplant may appear as myeloid sarcoma
Previous chemotherapy or radiation Increases the risk of AML in general

4. How does it look

On the body

What myeloid sarcoma looks like depends on where it grows.

Site Appearance
Skin Firm, painless, red, purple, brown or greenish lumps or plaques; may be single or many
Lymph nodes Swollen, rubbery glands, often mistaken for lymphoma
Around the eye Bulging of one eye (proptosis) or a swelling of the eyelid, especially in children
Gums Swollen gums, more typical of monocytic leukaemia
Breast A painless lump, which can look like breast cancer on imaging
Testis Painless swelling of a testis
Bone A swelling over a bone, often with pain

On scans

On CT or MRI, myeloid sarcoma usually appears as a solid soft-tissue mass. It may press on nearby structures, such as the spinal cord, bowel or bile ducts.

A PET-CT scan shows the tumour as an area of high activity. This scan is very useful for finding all sites of disease and for checking response after treatment.

Under the microscope

The pathologist sees sheets of medium-sized immature cells that wipe out the normal structure of the tissue. Without special stains, these cells can look very like lymphoma or other small round cell tumours.

Misdiagnosis was common in the past (Pileri et al., 2007). Special stains are therefore essential:

Marker Result
CD43 Usually positive (a useful screening marker)
Myeloperoxidase (MPO) Often positive in myeloid types
Lysozyme, CD68, CD163 Positive in monocytic types
CD33, CD117, CD34 Often positive
CD3, CD20 Negative, which helps rule out lymphoma

Myeloid sarcoma in children

Children with AML develop myeloid sarcoma more often than adults. It is particularly linked with AML carrying the t(8;21) change and with monocytic types of AML in infants.

In children, the tumour often appears around the eye, causing the eye to bulge, or in the skin. In babies, bluish-purple skin lumps are sometimes described as a “blueberry muffin” rash, which has several other possible causes.

Children are treated on the same childhood AML protocols as other children with AML. Their outlook is broadly similar to that of children without myeloid sarcoma who have the same genetic type of leukaemia.

Myeloid sarcoma and leukaemia cutis

Leukaemia cutis means leukaemia cells in the skin. Doctors use the term myeloid sarcoma when the cells form a distinct tumour that replaces the normal tissue.

In everyday practice the two overlap considerably, and both are treated as part of the underlying AML.

5. Symptoms

Symptoms depend on where the tumour grows and on whether leukaemia is also present in the blood and bone marrow.

Symptoms from the tumour itself

  • A lump or swelling in the skin, lymph nodes, breast or testis
  • Pain in the affected area, particularly in bone
  • Bulging eye, double vision or eyelid swelling
  • Back pain, leg weakness, numbness or problems with the bladder or bowel if the tumour presses on the spinal cord; this is an emergency
  • Abdominal pain, vomiting or bowel obstruction from tumours in the gut
  • Yellowing of the skin (jaundice) if the bile ducts are blocked
  • Headache, seizures or nerve problems if the brain or its coverings are involved
  • Breathlessness or chest pain from tumours in the chest

Symptoms of AML

If leukaemia is also present in the bone marrow, symptoms may include:

  • Tiredness, paleness and breathlessness from anaemia
  • Fevers and frequent infections from low white blood cells
  • Easy bruising, bleeding gums and nosebleeds from low platelets
  • Bone pain
  • Weight loss and night sweats

When to see a doctor

See a doctor promptly about any new, growing lump that does not go away within a few weeks. This is particularly important if you have had AML, MDS, a myeloproliferative neoplasm or a stem cell transplant.

Sudden back pain with leg weakness or numbness needs urgent assessment.

6. Diagnosis

Test Purpose
Biopsy of the lump Essential; confirms the diagnosis with special stains
Genetic tests on the biopsy Chromosome and gene studies (such as NPM1, FLT3, CBF fusions) guide treatment
Full blood count and blood film Look for leukaemia cells in the blood
Bone marrow test Shows whether AML is also present in the marrow
PET-CT Finds all sites of disease
MRI Used for the spine, brain or eye socket
Lumbar puncture Checks the spinal fluid if the brain or spine may be involved
Heart and organ function tests Check fitness for intensive chemotherapy

Diagnosis follows the World Health Organization classification (Khoury et al., 2022). The biopsy sample should be sent fresh where possible, so that genetic tests can be done.

7. Treatment

Because isolated myeloid sarcoma nearly always progresses to AML, systemic treatment is recommended even when there is no leukaemia in the bone marrow (Bakst et al., 2011). Treatment follows standard AML principles (Dohner et al., 2022).

Main treatments

Treatment When it is used
Intensive induction chemotherapy Standard first treatment for fit patients, usually cytarabine with an anthracycline (“7+3”)
Targeted drugs added to chemotherapy Midostaurin or quizartinib for FLT3-mutated disease; gemtuzumab ozogamicin for some types
Consolidation chemotherapy Further courses after remission to reduce the risk of relapse
Allogeneic stem cell transplant For higher-risk genetic types, relapse or myeloid sarcoma after previous treatment
Lower-intensity treatment Venetoclax with azacitidine or decitabine for older or less fit patients
Radiotherapy For tumours causing pressure (spinal cord, nerves, eye), tumours that remain after chemotherapy or when chemotherapy is not possible
Surgery Rarely needed, mainly to relieve obstruction or for diagnosis

Radiotherapy

Myeloid sarcoma is very sensitive to radiotherapy. Fairly low doses, often around 24 Gy in 12 treatments, usually control the tumour (Bakst et al., 2018).

Radiotherapy may be given urgently if the tumour is pressing on the spinal cord or threatening sight.

Relapse after transplant

When myeloid sarcoma appears after a transplant, treatment may include radiotherapy, chemotherapy and reducing immune-suppressing drugs or giving donor lymphocyte infusions. These help the donor immune system attack the leukaemia.

8. Outlook (prognosis)

The outlook for myeloid sarcoma is generally similar to that of AML with the same genetic features. The tumour itself does not appear to make the outlook worse once AML-type treatment is given (Avni et al., 2012).

Factor Effect on outlook
Genetic type Favourable types such as t(8;21), inv(16) and NPM1 without FLT3-ITD do better
Age and fitness Younger, fitter patients who can receive intensive treatment do better
Isolated myeloid sarcoma treated with chemotherapy Often a reasonable outlook
Myeloid sarcoma at relapse or after transplant More difficult to treat
Transformation from MDS or MPN Poorer outlook

In a large United States study, survival varied widely with age, site and treatment. People who received a stem cell transplant had better survival (Goyal et al., 2017).

Follow-up after treatment

After treatment ends, people are seen regularly for blood counts and examination. A PET-CT scan is often repeated to confirm that all tumours have gone.

In leukaemias with a measurable gene change, such as NPM1 or a CBF fusion, sensitive blood or marrow tests can detect tiny amounts of remaining disease (measurable residual disease). This helps doctors spot a relapse early and decide whether a transplant is needed.

9. Living with myeloid sarcoma

Treatment for myeloid sarcoma is the same demanding treatment used for AML, often with long hospital stays.

Concern What helps
Infections during chemotherapy Hand hygiene, preventive medicines and fast treatment of fever
Tiredness Rest balanced with gentle activity
Eating Small, frequent meals and dietitian advice
Emotional strain Psychological support, nurse specialists and patient groups
Fertility Discuss sperm or egg storage before treatment where possible

10. Frequently asked questions

Question Answer
Is myeloid sarcoma a type of sarcoma? No. Despite the name, it is a form of acute myeloid leukaemia
Why is chemotherapy needed if the bone marrow is clear? Because isolated myeloid sarcoma almost always progresses to AML without systemic treatment
Why is it called chloroma? Some tumours look green because of the enzyme myeloperoxidase
Is it inherited? No, except in rare families with inherited predisposition to AML
Can it come back? Yes, either as another lump or as AML in the marrow, so follow-up is important

11. Questions to ask your care team

  • Is there leukaemia in my bone marrow as well?
  • What genetic changes does the tumour have?
  • Which chemotherapy do you recommend?
  • Will I need radiotherapy or a stem cell transplant?
  • How will you check whether the treatment has worked?
  • What symptoms should make me contact the team urgently?

Resources

  1. Pileri, S.A. et al. (2007) ‘Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients’, Leukemia, 21(2), pp. 340-350.
  2. Bakst, R.L. et al. (2011) ‘How I treat extramedullary acute myeloid leukemia’, Blood, 118(14), pp. 3785-3793.
  3. Bakst, R.L. et al. (2018) ‘Use of radiation in extramedullary leukemia/chloroma: guidelines from the International Lymphoma Radiation Oncology Group’, International Journal of Radiation Oncology, Biology, Physics, 102(2), pp. 314-319.
  4. Avni, B. and Koren-Michowitz, M. (2011) ‘Myeloid sarcoma: current approach and therapeutic options’, Therapeutic Advances in Hematology, 2(5), pp. 309-316.
  5. Avni, B. et al. (2012) ‘Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma’, Hematological Oncology, 30(1), pp. 34-40.
  6. Shallis, R.M. et al. (2021) ‘Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved’, Blood Reviews, 47, p. 100773.
  7. Goyal, G. et al. (2017) ‘Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set’, Blood Cancer Journal, 7(8), e592.
  8. Dohner, H. et al. (2022) ‘Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN’, Blood, 140(12), pp. 1345-1377.
  9. Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms’, Leukemia, 36(7), pp. 1703-1719.
  10. National Cancer Institute (2026) Adult Acute Myeloid Leukemia Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.